A Novel Mechanism for Decreasing Plasma Lipid Level from Imidazoline I-1 Receptor Activation in High Fat Diet-fed Mice

Abstract

The imidazoline I-1 receptor (I-1 R) agonists are widely used to lower blood pressure, but their effects on hyperlipidemia are still obscure. The present study is aimed to evaluate the possible mechanism(s) of I-1 R in the regulation of lipid homeostasis. Farnesoid X receptor (FXR) plays an important role in blood lipid homeostasis; however, the role of FXR in rilmenidine-induced blood lipid lowering action is still unknown. Thus, we administered rilmenidine, a selective agonist of I-1 R, into high fat diet-fed (HFD) mice showing hypertriglyceridemia and hypercholesterolemia. Rilmenidine significantly ameliorated hyperlipidemia in HFD mice after 7 days of administration. Pretreatment with efaroxan, at a dose sufficient to inhibit I-1 R activation, blocked the effects of rilmenidine. Also, in cultured HepG2 cells, rilmenidine dose-dependently induced the expression of farnesoid X receptor (FXR). The rilmenidine-induced FXR expression and FXR-related genes were blocked by efaroxan. However, rilmenidine treatment did not affect the expression of enzymes related to β-oxidation. In conclusion, activation of I-1 R may activate FXR to lower plasma lipids, suggesting I-1 R as a new target for the treatment of hyperlipidemia.

Key words

cholesterol - efaroxan - imidazoline receptor - rilmenidine - triglyceride

References

• 1 Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease.  Diabetes. 1988;  37 1595-1607
• 2 McBride P. Triglycerides and risk for coronary artery disease.  Curr Atheroscler Rep. 2008;  10 386-390
• 3 Howard BV, Ruotolo G, Robbins DC. Obesity and dyslipidemia.  Endocrinol Metab Clin North Am. 2003;  32 855-867
• 4 Bousquet P. Identification and characterization of I1 imidazoline receptors: their role in blood pressure regulation.  Am J Hypertens. 2000;  13 84S-88S
• 5 Ernsberger P, Friedman JE, Koletsky RJ. The I1-imidazoline receptor: from binding site to therapeutic target in cardiovascular disease.  J Hypertens Suppl. 1997;  15 S9-S23
• 6 Velliquette RA, Kossover R, Previs SF, Ernsberger P. Lipid-lowering actions of imidazoline antihypertensive agents in metabolic syndrome X.  Naunyn Schmiedebergs Arch Pharmacol. 2006;  372 300-312
• 7 Lui TN, Tsao CW, Huang SY, Chang CH, Cheng JT. Activation of imidazoline I2B receptors is linked with AMP kinase pathway to increase glucose uptake in cultured C2C12 cells.  Neurosci Lett. 2010;  474 144-147
• 8 Raasch W, Schafer U, Chun J, Dominiak P. Biological significance of agmatine, an endogenous ligand at imidazoline binding sites.  Br J Pharmacol. 2001;  133 755-780
• 9 Lu TT, Repa JJ, Mangelsdorf DJ. Orphan nuclear receptors as eLiXiRs and FiXeRs of sterol metabolism.  J Biol Chem. 2001;  276 37735-37738
• 10 Repa JJ, Mangelsdorf DJ. The liver X receptor gene team: potential new players in atherosclerosis.  Nat Med. 2002;  8 1243-1248
• 11 Claudel T, Staels B, Kuipers F. The Farnesoid X receptor: a molecular link between bile acid and lipid and glucose metabolism.  Arterioscler Thromb Vasc Biol. 2005;  25 2020-2030
• 12 Watanabe M, Houten SM, Wang L, Moschetta A, Mangelsdorf DJ, Heyman RA, Moore DD, Auwerx J. Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c.  J Clin Invest. 2004;  113 1408-1418
• 13 Beyer TP, Schmidt RJ, Foxworthy P, Zhang Y, Dai J, Bensch WR, Kauffman RF, Gao H, Ryan TP, Jiang XC, Karathanasis SK, Eacho PI, Cao G. Coadministration of a liver X receptor agonist and a peroxisome proliferator activator receptor-alpha agonist in Mice: effects of nuclear receptor interplay on high-density lipoprotein and triglyceride metabolism in vivo.  J Pharmacol Exp Ther. 2004;  309 861-868
• 14 Kane CD, Stevens KA, Fischer JE, Haghpassand M, Royer LJ, Aldinger C, Landschulz KT, Zagouras P, Bagley SW, Hada W, Dullea R, Hayward CM, Francone OL. Molecular characterization of novel and selective peroxisome proliferator-activated receptor alpha agonists with robust hypolipidemic activity in vivo.  Mol Pharmacol. 2009;  75 296-306
• 15 Wang SR, Pessah M, Infante J, Catala D, Salvat C, Infante R. Lipid and lipoprotein metabolism in Hep G2 cells.  Biochim Biophys Acta. 1988;  961 351-363
• 16 Chapados NA, Seelaender M, Levy E, Lavoie JM. Effects of exercise training on hepatic microsomal triglyceride transfer protein content in rats.  Horm Metab Res. 2009;  41 287-393
• 17 Ji W, Gong BQ. Hypolipidemic effects and mechanisms of Panax notoginseng on lipid profile in hyperlipidemic rats.  J Ethnopharmacol. 2007;  113 318-324
• 18 Yu S, Rao S, Reddy JK. Peroxisome proliferator-activated receptors, fatty acid oxidation, steatohepatitis and hepatocarcinogenesis.  Curr Mol Med. 2003;  3 561-572
• 19 Goldwasser J, Cohen PY, Yang E, Balaguer P, Yarmush ML, Nahmias Y. Transcriptional regulation of human and rat hepatic lipid metabolism by the grapefruit flavonoid naringenin: role of PPARalpha, PPARgamma and LXRalpha.  PLoS One. 2010;  5 e12399
• 20 Chen N, Bezzina R, Hinch E, Lewandowski PA, Cameron-Smith D, Mathai ML, Jois M, Sinclair AJ, Begg DP, Wark JD, Weisinger HS, Weisinger RS. Green tea, black tea, and epigallocatechin modify body composition, improve glucose tolerance, and differentially alter metabolic gene expression in rats fed a high-fat diet.  Nutr Res. 2009;  29 784-793
• 21 Song S, Attia RR, Connaughton S, Niesen MI, Ness GC, Elam MB, Hori RT, Cook GA, Park EA. Peroxisome proliferator activated receptor alpha (PPARalpha) and PPAR gamma coactivator (PGC-1alpha) induce carnitine palmitoyltransferase IA (CPT-1A) via independent gene elements.  Mol Cell Endocrinol. 2010;  325 54-63
• 22 Zhang D, Christianson J, Liu ZX, Tian L, Choi CS, Neschen S, Dong J, Wood PA, Shulman GI. Resistance to high-fat diet-induced obesity and insulin resistance in mice with very long-chain acyl-CoA dehydrogenase deficiency.  Cell Metab. 2010;  11 402-411
• 23 Forman BM, Goode E, Chen J, Oro AE, Bradley DJ, Perlmann T, Noonan DJ, Burka LT, McMorris T, Lamph WW, Evans RM, Weinberger C. Identification of a nuclear receptor that is activated by farnesol metabolites.  Cell. 1995;  81 687-693
• 24 Zhang Y, Kast-Woelbern HR, Edwards PA. Natural structural variants of the nuclear receptor farnesoid X receptor affect transcriptional activation.  J Biol Chem. 2003;  278 104-110
• 25 Sinal CJ, Tohkin M, Miyata M, Ward JM, Lambert G, Gonzalez FJ. Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis.  Cell. 2000;  102 731-744
• 26 Edwards PA, Kast HR, Anisfeld AM. BAREing it all: the adoption of LXR and FXR and their roles in lipid homeostasis.  J Lipid Res. 2002;  43 2-12
• 27 Maloney PR, Parks DJ, Haffner CD, Fivush AM, Chandra G, Plunket KD, Creech KL, Moore LB, Wilson JG, Lewis MC, Jones SA, Willson TM. Identification of a chemical tool for the orphan nuclear receptor FXR.  J Med Chem. 2000;  43 2971-2974
• 28 Kast HR, Nguyen CM, Sinal CJ, Jones SA, Laffitte BA, Reue K, Gonzalez FJ, Willson TM, Edwards PA. Farnesoid X-activated receptor induces apolipoprotein C-II transcription: a molecular mechanism linking plasma triglyceride levels to bile acids.  Mol Endocrinol. 2001;  15 1720-1728
• 29 Zhang Y, Castellani LW, Sinal CJ, Gonzalez FJ, Edwards PA. Peroxisome proliferator-activated receptor-gamma coactivator 1alpha (PGC-1alpha) regulates triglyceride metabolism by activation of the nuclear receptor FXR.  Genes Dev. 2004;  18 157-169
• 30 Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver.  J Clin Invest. 2002;  109 1125-1131
• 31 Goldberg IJ, Scheraldi CA, Yacoub LK, Saxena U, Bisgaier CL. Lipoprotein ApoC-II activation of lipoprotein lipase. Modulation by apolipoprotein A-IV.  J Biol Chem. 1990;  265 4266-4272
• 32 Staels B, Vu-Dac N, Kosykh VA, Saladin R, Fruchart JC, Dallongeville J, Auwerx J. Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates.  J Clin Invest. 1995;  95 705-712
• 33 Claudel T, Inoue Y, Barbier O, Duran-Sandoval D, Kosykh V, Fruchart J, Fruchart JC, Gonzalez FJ, Staels B. Farnesoid X receptor agonists suppress hepatic apolipoprotein CIII expression.  Gastroenterology. 2003;  125 544-555
• 34 Blacklow SC. Versatility in ligand recognition by LDL receptor family proteins: advances and frontiers.  Curr Opin Struct Biol. 2007;  17 419-426
• 35 Ma PT, Gil G, Südhof TC, Bilheimer DW, Goldstein JL, Brown MS. Mevinolin, an inhibitor of cholesterol synthesis, induces mRNA for low density lipoprotein receptor in livers of hamsters and rabbits.  Proc Natl Acad Sci U S A. 1986;  83 8370-8374
• 36 Bilheimer DW, Grundy SM, Brown MS, Goldstein JL. Mevinolin and colestipol stimulate receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholesterolemia heterozygotes.  Proc Natl Acad Sci USA. 1983;  80 4124-4128
• 37 Cayla C, Schaak S, Roquelaine C, Gales C, Quinchon F, Paris H. Homologous regulation of the alpha2C-adrenoceptor subtype in human hepatocarcinoma, HepG2.  Br J Pharmacol. 1999;  126 69-78
• 38 Charlton-Menys V, Durrington PN. Human cholesterol metabolism and therapeutic molecules.  Exp Physiol. 2008;  93 27-42

1 These authors contributed equally to this work.

Correspondence